Paratek Pharmaceuticals (NASDAQ:PRTK) Reaches New 1-Year High at $11.23

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) hit a new 52-week high on Thursday . The stock traded as high as $11.23 and last traded at $10.93, with a volume of 1529242 shares. The stock had previously closed at $10.13.

Several equities research analysts recently weighed in on PRTK shares. Jefferies Financial Group initiated coverage on Paratek Pharmaceuticals in a report on Tuesday, March 2nd. They set a “buy” rating and a $15.00 price target for the company. Zacks Investment Research raised Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 19th. WBB Securities raised Paratek Pharmaceuticals from a “speculative buy” rating to a “buy” rating and set a $10.00 target price for the company in a report on Thursday, April 29th. Finally, SVB Leerink reissued a “buy” rating and issued a $14.00 target price on shares of Paratek Pharmaceuticals in a report on Thursday, March 4th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Paratek Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $13.60.

The stock has a market cap of $512.92 million, a price-to-earnings ratio of -5.73 and a beta of 1.57. The company’s 50-day simple moving average is $8.03.

Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings results on Monday, May 17th. The specialty pharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.17). The firm had revenue of $16.43 million during the quarter, compared to analyst estimates of $32.83 million. On average, sell-side analysts expect that Paratek Pharmaceuticals, Inc. will post -0.11 EPS for the current year.

In related news, General Counsel William M. Haskel sold 7,561 shares of Paratek Pharmaceuticals stock in a transaction dated Friday, June 4th. The stock was sold at an average price of $9.70, for a total transaction of $73,341.70. Following the completion of the sale, the general counsel now owns 364,653 shares in the company, valued at approximately $3,537,134.10. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman Michael Bigham sold 34,364 shares of Paratek Pharmaceuticals stock in a transaction dated Friday, June 4th. The stock was sold at an average price of $9.70, for a total value of $333,330.80. Following the sale, the chairman now owns 913,676 shares of the company’s stock, valued at approximately $8,862,657.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 59,107 shares of company stock valued at $573,338. Company insiders own 5.10% of the company’s stock.

A number of institutional investors have recently bought and sold shares of PRTK. BlackRock Inc. boosted its stake in Paratek Pharmaceuticals by 0.9% in the 1st quarter. BlackRock Inc. now owns 3,478,440 shares of the specialty pharmaceutical company’s stock worth $24,557,000 after buying an additional 31,111 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Paratek Pharmaceuticals by 40.6% in the 4th quarter. Renaissance Technologies LLC now owns 761,220 shares of the specialty pharmaceutical company’s stock worth $4,765,000 after buying an additional 219,800 shares during the last quarter. Geode Capital Management LLC boosted its stake in Paratek Pharmaceuticals by 9.5% in the 1st quarter. Geode Capital Management LLC now owns 695,015 shares of the specialty pharmaceutical company’s stock worth $4,906,000 after buying an additional 60,355 shares during the last quarter. Trellus Management Company LLC boosted its stake in Paratek Pharmaceuticals by 13.3% in the 4th quarter. Trellus Management Company LLC now owns 340,000 shares of the specialty pharmaceutical company’s stock worth $2,128,000 after buying an additional 40,000 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Paratek Pharmaceuticals by 1.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 271,478 shares of the specialty pharmaceutical company’s stock worth $1,700,000 after buying an additional 4,146 shares during the last quarter. Hedge funds and other institutional investors own 51.11% of the company’s stock.

About Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris.

Read More: What are convertible shares? 

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.